Remove Biochemical Assays Remove Therapies Remove Webinar
article thumbnail

The future of cancer immunotherapy: exclusive webinar

Drug Discovery World

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

article thumbnail

Learn about cancer immunotherapy in this webinar

Drug Discovery World

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. How does “potency” apply to cell and gene therapy (CGT) products?